Published guidance, NICE advice and quality standards | Guidance

Showing 271 to 280 of 882

Sort by

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma	TA865	8 February 2023	8 February 2023
Upadacitinib for treating active non-radiographic axial spondyloarthritis	TA861	1 February 2023	1 February 2023
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments	TA862	1 February 2023	1 February 2023
Somatrogon for treating growth disturbance in children and young people aged 3 years and over	TA863	1 February 2023	1 February 2023
Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted	TA864	1 February 2023	1 February 2023
Maribavir for treating refractory cytomegalovirus infection after transplant	TA860	18 January 2023	18 January 2023
Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal)	TA859	16 January 2023	16 January 2023
Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma	TA857	11 January 2023	11 January 2023
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma	TA858	11 January 2023	11 January 2023
Upadacitinib for treating moderately to severely active ulcerative colitis	TA856	4 January 2023	4 January 2023